

Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N1737D888BD7EN.html>

Date: April 2022

Pages: 342

Price: US\$ 2,500.00 (Single User License)

ID: N1737D888BD7EN

Abstracts

Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 40, 31, 3, 2, 19, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 9 and 1 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Nasopharyngeal Cancer - Overview

Nasopharyngeal Cancer - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Nasopharyngeal Cancer - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nasopharyngeal Cancer - Companies Involved in Therapeutics Development

Nasopharyngeal Cancer - Drug Profiles

Nasopharyngeal Cancer - Dormant Projects

Nasopharyngeal Cancer - Discontinued Products

Nasopharyngeal Cancer - Product Development Milestones

Featured News & Press Releases

Apr 19, 2022: BeiGene presents updated results from phase 3 RATIONALE-309 Trial of PD-1 inhibitor Tislelizumab in first-line RM-NPC in Virtual ASCO Plenary Series

Apr 08, 2022: Junshi Biosciences and Coherus present results of phase 3 study of toripalimab in first line treatment of recurrent or metastatic nasopharyngeal carcinoma at 2022 AACR Annual Meeting

Mar 07, 2022: Voluntary announcement - JS001sc injection received the clinical trial approval

Dec 10, 2021: BeiGene presents results from phase 3 trial of Tislelizumab in nasopharyngeal cancer at ESMO Immuno-Oncology Congress 2021

Dec 03, 2021: Junshi Biosciences announces two additional indications for toripalimab included in China's National Reimbursement Drug List

Dec 02, 2021: BeiGene to present new clinical data on Tislelizumab at ESMO IO Congress 2021

Nov 29, 2021: Junshi Biosciences announces approval of supplemental new drug application by NMPA for Toripalimab in combination with Cisplatin and Gemcitabine as first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma

Nov 20, 2021: Sichuan Kelun Pharmaceutical Co : Announcement on the acceptance of the listing application for PD-L1 new drug Tetlizumab injection by NMPA

Nov 01, 2021: Coherus and Junshi Biosciences announce FDA acceptance of BLA filing for toripalimab for treatment of nasopharyngeal carcinoma

Oct 31, 2021: Shanghai Junshi Bioscience Co: Voluntary announcement -the FDA accepted biologics license application of Toripalimab for treatment of nasopharyngeal carcinoma

Oct 06, 2021: Viracta Therapeutics initiates phase 1b/2 trial in Epstein-Barr Virus-Positive (EBV+) solid tumors

Sep 20, 2021: Pembrolizumab does not prolong overall survival compared to chemotherapy in platinum-pretreated recurrent or metastatic nasopharyngeal carcinoma

Sep 15, 2021: Coherus and Junshi Biosciences announce results from phase 3 study of toripalimab published in September Issue of Nature Medicine

Sep 01, 2021: Coherus and Junshi Biosciences announce completion of rolling BLA submission to U.S. FDA for toripalimab for the treatment of nasopharyngeal carcinoma

Aug 22, 2021: BeiGene announces acceptance of a supplemental biologics license application in China for tislelizumab in nasopharyngeal cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Nasopharyngeal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Nasopharyngeal Cancer - Pipeline by ADC Therapeutics SA, 2022
Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, 2022
Nasopharyngeal Cancer - Pipeline by Akeso Inc, 2022
Nasopharyngeal Cancer - Pipeline by Alphamab Oncology, 2022
Nasopharyngeal Cancer - Pipeline by Ambrx Biopharma Inc, 2022
Nasopharyngeal Cancer - Pipeline by Amgen Inc, 2022
Nasopharyngeal Cancer - Pipeline by Apollomics Inc, 2022
Nasopharyngeal Cancer - Pipeline by Ascentage Pharma Group International, 2022
Nasopharyngeal Cancer - Pipeline by Astex Pharmaceuticals Inc, 2022
Nasopharyngeal Cancer - Pipeline by AstraZeneca Plc, 2022
Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, 2022
Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals Inc, 2022
Nasopharyngeal Cancer - Pipeline by BeiGene Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by BioSyngen Pte Ltd, 2022
Nasopharyngeal Cancer - Pipeline by BP InnoMed Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
Nasopharyngeal Cancer - Pipeline by Chengdu Wonho Biology Engineering Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by China Immunotech Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Compugen Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Eli Lilly and Co, 2022
Nasopharyngeal Cancer - Pipeline by EpimAb Biotherapeutics Inc, 2022
Nasopharyngeal Cancer - Pipeline by Eutilex Co Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Exelixis Inc, 2022

Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Geneius Biotechnology Inc, 2022

Nasopharyngeal Cancer - Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2022

Nasopharyngeal Cancer - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2022

Nasopharyngeal Cancer - Pipeline by GeoVax Labs Inc, 2022

Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, 2022

Nasopharyngeal Cancer - Pipeline by Guangzhou Bairui Biomedical Technology Co Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Guangzhou Double Bioproduct Inc, 2022

Nasopharyngeal Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022

Nasopharyngeal Cancer - Pipeline by HRYZ (ShenZhen) Biotech Co, 2022

Nasopharyngeal Cancer - Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Immix BioPharma Inc, 2022

Nasopharyngeal Cancer - Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Immunomic Therapeutics Inc, 2022

Nasopharyngeal Cancer - Pipeline by Incyte Corp, 2022

Nasopharyngeal Cancer - Pipeline by Inhibrx Inc, 2022

Nasopharyngeal Cancer - Pipeline by Inmune Bio Inc, 2022

Nasopharyngeal Cancer - Pipeline by Innovent Biologics Inc, 2022

Nasopharyngeal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Johnson & Johnson, 2022

Nasopharyngeal Cancer - Pipeline by Joint Biosciences Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Karyopharm Therapeutics Inc, 2022

Nasopharyngeal Cancer - Pipeline by Kur Therapeutics Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Lion TCR Pte Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Merck & Co Inc, 2022

Nasopharyngeal Cancer - Pipeline by Merck KGaA, 2022

Nasopharyngeal Cancer - Pipeline by Molecular Targeting Technologies Inc, 2022

Nasopharyngeal Cancer - Pipeline by Neonc Technologies Inc, 2022

Nasopharyngeal Cancer - Pipeline by Novartis AG, 2022

Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Oxford Vacmedix UK Ltd, 2022

Nasopharyngeal Cancer - Pipeline by Polaris Pharmaceuticals Inc, 2022

Nasopharyngeal Cancer - Pipeline by Qilu Puget Sound Biotherapeutics Corp, 2022

Nasopharyngeal Cancer - Pipeline by Rapa Therapeutics LLC, 2022

Nasopharyngeal Cancer - Pipeline by RAPT Therapeutics Inc, 2022

Nasopharyngeal Cancer - Pipeline by Rubius Therapeutics Inc, 2022
Nasopharyngeal Cancer - Pipeline by Seven and Eight Biopharmaceuticals Corp, 2022
Nasopharyngeal Cancer - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Shanghai GeneChem Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Shanghai Miracogen Inc, 2022
Nasopharyngeal Cancer - Pipeline by Shenghe (China) Biopharmaceutical Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Soricimed Biopharma Inc, 2022
Nasopharyngeal Cancer - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by TCR Cure Biopharma Technology Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Ltd, 2022
Nasopharyngeal Cancer - Pipeline by TOT Biopharm Co Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Transcenta Holding Ltd, 2022
Nasopharyngeal Cancer - Pipeline by Vectorite Biomedical Inc, 2022
Nasopharyngeal Cancer - Pipeline by Viracta Therapeutics Inc, 2022
Nasopharyngeal Cancer - Pipeline by Xencor Inc, 2022
Nasopharyngeal Cancer - Pipeline by Xiangxue Life Sciences, 2022
Nasopharyngeal Cancer - Pipeline by Y-Biologics Inc, 2022
Nasopharyngeal Cancer - Dormant Projects, 2022
Nasopharyngeal Cancer - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Nasopharyngeal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Nasopharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N1737D888BD7EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N1737D888BD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

